Product Information
DOXAZOSIN MESYLATE 1 MG TAB is a generic product labeled by Mylan Pharmaceuticals Inc., priced at $0.0779 per EA under NDC 59762241007. Its NADAC has been published 218 times since Mar 23, 2022.
FDA first approved this application on Nov 2, 1990. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the doxazosin market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
1 mg/1
Manufacturer
Mylan Pharmaceuticals Inc.NDC
59762241007
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
5/20/2026
Active Ingredients
DOXAZOSIN MESYLATEApproval Type
Authorized Generic (NDA)
FDA Application
NDA019668FDA Approved
11/2/1990
TE Code
AB
On Market Since
11/3/2021
Pharmacological Classes
Price Statistics
The NADAC for DOXAZOSIN MESYLATE 1 MG TAB has been published 218 times since Mar 23, 2022, and over the history we have for it it has declined 17.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0779 per EA |
|---|---|
| All-time high | $0.1037 (Dec 14, 2022) |
| All-time low | $0.0632 (Jan 18, 2023) |
| 52-week high | $0.0856 |
| 52-week low | $0.0766 |
| Median price | $0.0810 |
| Average price | $0.0803 |
| Largest weekly change | +55.9% (Feb 22, 2023) |
| Weeks tracked | 218 |
| Tracking since | Mar 23, 2022 |
1W
N/A
1M
N/A
3M
N/A
6M
-3.9%
1Y
-7.2%
3Y
-1.8%
5Y
N/A
All
-17.1%
Last surveyed May 20, 2026 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the doxazosin market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Mylan Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
doxazosin market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
alpha-Adrenergic Blocker class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of DOXAZOSIN MESYLATE 1 MG TAB?
The current National Average Drug Acquisition Cost (NADAC) for DOXAZOSIN MESYLATE 1 MG TAB, manufactured by Mylan Pharmaceuticals Inc., is $0.0779 per EA (NDC 59762241007), effective May 20, 2026.
How has the price of DOXAZOSIN MESYLATE 1 MG TAB changed over time?
Over the history we have for it, the NADAC for DOXAZOSIN MESYLATE 1 MG TAB has declined 17.1%. It has been tracked across 218 weekly CMS publications since Mar 23, 2022.
What are the highest and lowest recorded NADAC prices for DOXAZOSIN MESYLATE 1 MG TAB?
Since Mar 23, 2022, the NADAC for DOXAZOSIN MESYLATE 1 MG TAB has ranged from a low of $0.0632 (Jan 18, 2023) to a high of $0.1037 (Dec 14, 2022), with a median of $0.0810 per EA.
Are there cheaper alternatives to DOXAZOSIN MESYLATE 1 MG TAB?
No other NADAC-published product currently shares the active ingredient and strength of DOXAZOSIN MESYLATE 1 MG TAB in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures DOXAZOSIN MESYLATE 1 MG TAB?
DOXAZOSIN MESYLATE 1 MG TAB (NDC 59762241007) is labeled by Mylan Pharmaceuticals Inc., and CMS classifies it as a generic product.